Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Rafal DziadziuszkoMatthew G KrebsFilippo De BraudSalvatore SienaAlexander E DrilonRobert C DoebeleManish R PatelByoung Chul ChoStephen V LiuMyung-Ju AhnChao-Hua ChiuAnna F FaragoChia-Chi LinChristos S KarapetisYu-Chung LiBann-Mo DayDavid ChenTimothy R WilsonFabrice BarlesiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Entrectinib continued to demonstrate a high level of clinical benefit for patients with ROS1 fusion-positive NSCLC, including patients with CNS metastases.
Keyphrases
- locally advanced
- small cell lung cancer
- squamous cell carcinoma
- cell death
- dna damage
- reactive oxygen species
- rectal cancer
- neoadjuvant chemotherapy
- blood brain barrier
- advanced non small cell lung cancer
- radiation therapy
- phase ii study
- clinical trial
- oxidative stress
- study protocol
- open label
- epidermal growth factor receptor